Advancing Science. Improving Connections.
Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain orphan diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of NeuropsychopharmacologyRead More
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of NeuropsychopharmacologyRead More
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental DisordersRead More
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion SyndromeRead More